06:25:27 EDT Fri 07 May 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:GLPG from 2020-05-08 to 2021-05-07 - 21 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2021-03-12 04:55U:GLPGNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
2021-03-03 03:20U:GLPGNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
2021-03-03 03:20U:GLPGNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
2021-02-19 01:05U:GLPGNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
2021-02-10 09:00U:GLPGNews ReleaseGalapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF
2021-01-04 16:05U:GLPGNews ReleaseSelvita completes acquisition of Fidelta from Galapagos
2020-12-15 16:15U:GLPGNews ReleaseGilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca ® (Filgotinib)
2020-12-10 17:17U:GLPGNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
2020-12-10 17:17U:GLPGNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
2020-11-23 16:15U:GLPGNews ReleaseSelvita to acquire Fidelta from Galapagos
2020-11-02 16:01U:GLPGNews ReleaseEuropean Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis
2020-10-12 09:15U:GLPGNews ReleasePhase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis
2020-09-25 13:00U:GLPGNews ReleaseEuropean Commission Grants Marketing Authorization for Jyseleca ® ? (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
2020-08-29 19:38U:GLPGNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
2020-08-25 22:45U:GLPGNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
2020-08-20 17:29U:GLPGNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
2020-08-19 20:01U:GLPGNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
2020-07-24 08:10U:GLPGNews ReleaseGilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca ® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis
2020-06-05 16:01U:GLPGNews ReleaseNew Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis
2020-06-04 01:29U:GLPGNews ReleaseFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
2020-05-20 16:03U:GLPGNews ReleaseGilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis